FLNA Filana Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why FLNA matters now
Filana Therapeutics, Inc. (FLNA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.18 with -0.84% on the session and $57.0M in market capitalization; recent performance reads 1-month +1.67% and YTD -40.49%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.3M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -151.4%.
The latest indexable market news headline is "Filana Therapeutics Reports Q1 2026 Financial Results and Business Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.86
P/S
0.00
EV/EBITDA
0.36
DCF Value
$1.85
FCF Yield
-151.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-99.8%
ROA
-71.9%
ROIC
-120.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.3M | $-0.21 |
| Q4 2025 | $0.00 | $-12.5M | $-0.26 |
| FY 2025 | $0.00 | $-91.0M | $-1.88 |
| Q3 2025 | $0.00 | $-10.8M | $-0.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.78
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.